Mostrar el registro sencillo del ítem

dc.contributor.author
Qiao, Liang  
dc.contributor.author
Yacoub, Adly  
dc.contributor.author
McKinstry, Robert  
dc.contributor.author
Park, Jong Sung  
dc.contributor.author
Caron, Ruben Walter  
dc.contributor.author
Fisher, Paul B.  
dc.contributor.author
Hagan, Michael P.  
dc.contributor.author
Grant, Steven  
dc.contributor.author
Dent, Paul  
dc.date.available
2021-03-12T16:02:07Z  
dc.date.issued
2002-12  
dc.identifier.citation
Qiao, Liang; Yacoub, Adly; McKinstry, Robert; Park, Jong Sung; Caron, Ruben Walter; et al.; Pharmocologic inhibitors of the mitogen activated protein kinase cascade have the potential to interact with ionizing radiation exposure to induce cell death in carcinoma cells by multiple mechanisms; Taylor & Francis; Cancer Biology & Therapy; 1; 2; 12-2002; 168-176  
dc.identifier.issn
1538-4047  
dc.identifier.uri
http://hdl.handle.net/11336/128235  
dc.description.abstract
Recent studies have shown that inhibition of stress-induced signaling via the mitogen activated protein kinase (MAPK) pathway can potentiate the toxic effects of chemotherapeutic drugs and ionizing radiation. Because of these observations, we have further investigated the impact upon growth and survival of mammary (MDA-MB-231, MCF7, T47D), prostate (DU145, LNCaP, PC3) and squamous (A431) carcinoma cells following irradiation and combined long-term exposure to MEK1/2 inhibitors. Exposure of carcinoma cells to ionizing radiation resulted in MAPK pathway activation initially (0-4h) and modestly enhanced MAPK activity at later times (24h-96h). Inhibition of radiation-induced MAPK activation using MEK1/2 inhibitors potentiated radiation-induced apoptosis in two waves, at 21-30h and 96-144h after exposure. The potentiation of apoptosis was not observed in MCF7, LNCaP, or PC3 cells. At 24h, the potentiation of apoptosis was independent of radiation dose whereas at 108h, apoptosis correlated with increasing dose. Removal of the MEK1/2 inhibitor either 6h or 12h after exposure abolished the potentiation of apoptosis at 24h. At this time, the potentiation of apoptosis correlated with cleavage of pro-caspases -8, -9 and -3, and with release of cytochrome c into the cytosol. Inhibition of caspase function using a pan-caspase inhibitor ZVAD blocked the enhanced apoptotic response at 24h. Selective inhibition of caspase 9 with LEHD or caspase 8 with IETD partially blunted the apoptotic response in MDA-MB-231, DU145 and A431 cells, whereas inhibition of both caspases reduced the response by >90%. Removal of the MEK1/2 inhibitor either 24h or 48h after exposure abolished the potentiation of apoptosis at 108h. Incubation of cells with ZVAD for 108h also abolished the potentiation of apoptosis. In general agreement with the finding that prolonged inhibition of MEK1/2 was required to enhance radiation-induced apoptosis at 108h, omission of MEK1/2 inhibitor from the culture media during assessment of clonogenic survival resulted in either little or no significant alteration in radiosensitivity. Collectively, our data show that combined exposure to radiation and MEK1/2 inhibitors can reduce survival in some, but not all, tumor cell types. Prolonged blunting of MAPK pathway function following radiation exposure is required for MEK1/2 inhibitors to have any effect on carcinoma cell radiosensitivity.  
dc.format
application/pdf  
dc.language.iso
eng  
dc.publisher
Taylor & Francis  
dc.rights
info:eu-repo/semantics/openAccess  
dc.rights.uri
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/  
dc.subject
APOPTOSIS  
dc.subject
CASPASE  
dc.subject
IONIZING RADIATION  
dc.subject
MAP KINASE  
dc.subject
MAPK  
dc.subject
SURVIVAL  
dc.subject.classification
Otras Ciencias Médicas  
dc.subject.classification
Otras Ciencias Médicas  
dc.subject.classification
CIENCIAS MÉDICAS Y DE LA SALUD  
dc.title
Pharmocologic inhibitors of the mitogen activated protein kinase cascade have the potential to interact with ionizing radiation exposure to induce cell death in carcinoma cells by multiple mechanisms  
dc.type
info:eu-repo/semantics/article  
dc.type
info:ar-repo/semantics/artículo  
dc.type
info:eu-repo/semantics/publishedVersion  
dc.date.updated
2021-01-18T15:48:23Z  
dc.identifier.eissn
1555-8576  
dc.journal.volume
1  
dc.journal.number
2  
dc.journal.pagination
168-176  
dc.journal.pais
Reino Unido  
dc.journal.ciudad
Londres  
dc.description.fil
Fil: Qiao, Liang. Virginia Commonwealth University; Estados Unidos  
dc.description.fil
Fil: Yacoub, Adly. Virginia Commonwealth University; Estados Unidos  
dc.description.fil
Fil: McKinstry, Robert. Virginia Commonwealth University; Estados Unidos  
dc.description.fil
Fil: Park, Jong Sung. Virginia Commonwealth University; Estados Unidos  
dc.description.fil
Fil: Caron, Ruben Walter. Virginia Commonwealth University; Estados Unidos. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Mendoza. Instituto de Medicina y Biología Experimental de Cuyo; Argentina  
dc.description.fil
Fil: Fisher, Paul B.. Columbia University. College of Physicians and Surgeons; Estados Unidos  
dc.description.fil
Fil: Hagan, Michael P.. Virginia Commonwealth University; Estados Unidos  
dc.description.fil
Fil: Grant, Steven. Virginia Commonwealth University; Estados Unidos  
dc.description.fil
Fil: Dent, Paul. Virginia Commonwealth University; Estados Unidos  
dc.journal.title
Cancer Biology & Therapy  
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/doi/https://doi.org/10.4161/cbt.64  
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/url/https://www.tandfonline.com/doi/abs/10.4161/cbt.64